E. Furr Stimming, V. Sung, C. Testa, S. Kostyk, C. Ross, A. Samii, M. Geschwind, Deborah Hall, P. Dayalu, R. Lonser, Brad Elder, P. Larson, David L. Cooper, Marcie Clarkin, T. Ali, R. Dolmetsch
{"title":"amt-130 (HD-genetrx-1)治疗早期亨廷顿舞蹈病(HD)的双盲、剂量递增I/II期临床试验队列1的中期结果","authors":"E. Furr Stimming, V. Sung, C. Testa, S. Kostyk, C. Ross, A. Samii, M. Geschwind, Deborah Hall, P. Dayalu, R. Lonser, Brad Elder, P. Larson, David L. Cooper, Marcie Clarkin, T. Ali, R. Dolmetsch","doi":"10.1136/jnnp-2022-ehdn.255","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":251913,"journal":{"name":"J: Clinical therapeutics","volume":"1 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2022-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":"{\"title\":\"J05 Interim results from cohort 1 of the double-blind, dose-escalation phase I/II clinical trial of amt-130 (HD-genetrx-1) for early-stage huntington’s disease (HD)\",\"authors\":\"E. Furr Stimming, V. Sung, C. Testa, S. Kostyk, C. Ross, A. Samii, M. Geschwind, Deborah Hall, P. Dayalu, R. Lonser, Brad Elder, P. Larson, David L. Cooper, Marcie Clarkin, T. Ali, R. Dolmetsch\",\"doi\":\"10.1136/jnnp-2022-ehdn.255\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":251913,\"journal\":{\"name\":\"J: Clinical therapeutics\",\"volume\":\"1 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"J: Clinical therapeutics\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1136/jnnp-2022-ehdn.255\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"J: Clinical therapeutics","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1136/jnnp-2022-ehdn.255","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
J05 Interim results from cohort 1 of the double-blind, dose-escalation phase I/II clinical trial of amt-130 (HD-genetrx-1) for early-stage huntington’s disease (HD)